[{"address1": "2929 7th Street", "address2": "Suite 105", "city": "Berkeley", "state": "CA", "zip": "94710", "country": "United States", "phone": "510 982 6030", "website": "https://cariboubio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel E. Haurwitz Ph.D.", "age": 38, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 832920, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy P. Kelly M.B.A.", "age": 55, "title": "Chief Technology Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 730050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Barbara G. McClung Esq., J.D.", "age": 69, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 668622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sriram  Ryali M.B.A.", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Poon", "title": "Vice President of Operations & Information Technology", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Fischesser", "title": "Interim Principal Accounting Officer & Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Figueroa C.F.A.", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Reigin  Zawadzki", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruhi A. Khan M.B.A.", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 573900, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tina  Albertson M.D., Ph.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.5, "open": 2.57, "dayLow": 2.45, "dayHigh": 2.6, "regularMarketPreviousClose": 2.5, "regularMarketOpen": 2.57, "regularMarketDayLow": 2.45, "regularMarketDayHigh": 2.6, "payoutRatio": 0.0, "beta": 2.591, "forwardPE": -1.2512562, "volume": 654333, "regularMarketVolume": 654333, "averageVolume": 1123207, "averageVolume10days": 1014210, "averageDailyVolume10Day": 1014210, "bid": 1.85, "ask": 3.16, "bidSize": 2, "askSize": 2, "marketCap": 231876864, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 3.0, "allTimeHigh": 32.645, "allTimeLow": 0.66, "priceToSalesTrailing12Months": 25.422308, "fiftyDayAverage": 2.1286, "twoHundredDayAverage": 1.491, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 73779864, "profitMargins": 0.0, "floatShares": 84057692, "sharesOutstanding": 93123239, "sharesShort": 3672865, "sharesShortPriorMonth": 4112720, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0394, "heldPercentInsiders": 0.09814999, "heldPercentInstitutions": 0.41926998, "shortRatio": 2.65, "shortPercentOfFloat": 0.041300002, "impliedSharesOutstanding": 93497228, "bookValue": 1.784, "priceToBook": 1.3957399, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -164263008, "trailingEps": -1.78, "forwardEps": -1.99, "enterpriseToRevenue": 8.089, "enterpriseToEbitda": -0.504, "52WeekChange": 0.32446814, "SandP52WeekChange": 0.16625166, "quoteType": "EQUITY", "currentPrice": 2.49, "targetHighPrice": 32.0, "targetLowPrice": 1.0, "targetMeanPrice": 8.85714, "targetMedianPrice": 5.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 183948000, "totalCashPerShare": 1.975, "ebitda": -146260992, "totalDebt": 25851000, "quickRatio": 6.464, "currentRatio": 6.664, "totalRevenue": 9121000, "debtToEquity": 15.561, "revenuePerShare": 0.099, "returnOnAssets": -0.31775, "returnOnEquity": -0.68931997, "grossProfits": -119863000, "freeCashflow": -79720248, "operatingCashflow": -133114000, "revenueGrowth": -0.23, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -13.28384, "financialCurrency": "USD", "symbol": "CRBU", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NMS", "messageBoardId": "finmb_272189231", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1761349968, "regularMarketTime": 1761336001, "shortName": "Caribou Biosciences, Inc.", "longName": "Caribou Biosciences, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1627047000000, "epsTrailingTwelveMonths": -1.78, "epsForward": -1.99, "epsCurrentYear": -1.64, "priceEpsCurrentYear": -1.5182927, "fiftyDayAverageChange": 0.36140013, "fiftyDayAverageChangePercent": 0.16978303, "twoHundredDayAverageChange": 0.99899995, "twoHundredDayAverageChangePercent": 0.67002004, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-23", "cryptoTradeable": false, "marketState": "CLOSED", "postMarketChangePercent": 0.401606, "postMarketPrice": 2.5, "postMarketChange": 0.00999999, "regularMarketChange": -0.00999999, "regularMarketDayRange": "2.45 - 2.6", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1123207, "fiftyTwoWeekLowChange": 1.8299999, "fiftyTwoWeekLowChangePercent": 2.772727, "fiftyTwoWeekRange": "0.66 - 3.0", "fiftyTwoWeekHighChange": -0.51, "fiftyTwoWeekHighChangePercent": -0.17, "fiftyTwoWeekChangePercent": 32.446815, "earningsTimestampStart": 1762977600, "earningsTimestampEnd": 1762977600, "isEarningsDateEstimate": true, "regularMarketChangePercent": -0.4, "regularMarketPrice": 2.49, "displayName": "Caribou Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-10-25"}]